



Drug Precursor Control Screening

1 February 2006, Brussels

***Suzanne Stauffer
European Commission
DG TAXUD-C1***

Drug Precursor Control in the Community

1. Background
2. Community legislation
3. Principle requirements
4. Challenges
5. Operational side
6. Future developments



1. Background

- UNODC World Drugs' Report 2005: EC remains the most important XTC source
- 10.000 XTC tablets = 1 liter 3,4 MDP-2-P
- 3,4 Methylenedioxyphenyl-2-propanone (or "PMK")= Category 1 drug precursor and the key substance used in the XTC manufacture
- **PMK** has also licit uses: used to obtain components of parfume
- No prohibition – but control



.../...

- **Ephedrine/pseudo-ephedrine** = cold medicine versus methamphetamine
- **Acetic Anhydride**= Aspirin versus Heroin
- **Potassium Permanganate**: Purifying of Water versus Cocaine



.../...

- United Nations Convention against illicit traffic in narcotic drugs and psychotropic substances of 1988
- Article 12 of the 1988 Convention
- To focus on « supply side » : « Without Chemicals no Drugs »
- EC participated in the negotiations of Article 12 and implemented the requirements in 1990 and 1992



.. / ..

- Original intention: contribution by industrialised countries to the efforts requested from the drug producing countries
- Control of domestic distribution and exports
- Community used to be a producer and exporter only
- Today: Community has also become a place of illicit (synthetic) drug manufacture and has also become an importer of drug precursors



2. Community legislation

- Since 18th August 2005: New Community legislation
- External trade:

Council Regulation (EC) No 111/2005 of 22 December 2004 laying down rules for the monitoring of trade between the Community and third countries in drug precursors
OJ L 22 of 26 January 2005

Replaced Council Regulation (EC) No 3677/90



../..

- Intra-Community trade:

Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors
OJ L 47 of 18 February 2004

Responsible Service: DG Enterprise – Ms. Laurence Cordier tel. +32.2.296.4843 email: Laurence.Cordier@cec.eu.int

../..



.../...

- Joint Implementing Regulation:

New **Commission Regulation (EC) No 1277/2005**

laying down implementing rules for Regulation (EC) No 273/2004 and Regulation (EC) No 111/2005

OJ L 202 3rd August 2005, p. 7

Partly replaced Commission Regulation (EC)

No 3769/92





- **Bilateral agreements with the main players**
 - **Andean Countries (1995)**
 - OJ L 324 of 30/12/1995
 - **Mexico (1997)**
 - OJ L 77 of 19/3/1997, p. 22
 - **United States (1997)**
 - OJ L 164 of 21/6/1997 p. 22
 - **Chile (1998)**
 - OJ L 336 of 11/12/1998 p. 46
 - **Turkish Republic (2003)**



.../...

- Agreement between the European Community and the Turkish Republic (OJ L 64 of 2.3.2003 p. 28 – entry into force 1st August 2004)
 - Aim: to foster co-operation
 - However: Community regulations are the legal instruments relevant for accession and must be applied **not** the provisions of the bilateral agreement!



3. Principle requirements

- Concerns trade between the Community and third countries
- Council Regulation (EC) No 111/2005 and Commission Regulation (EC) No 1277/2005
- Basic pattern remains diversion from legal trade
- Main aim: to monitor trade + to prevent diversion



.../...

- **Chemicals:**
 - 23 scheduled substances
 - 3 Categories
 - includes: pure substance, mixtures, natural products
 - principally excludes: medicinal products, pharmaceutical preparations - EC has strong controls over distribution of medicinal products
- **EC Voluntary Monitoring List**



.../...

- **Documentation**
- **Labelling**
- **Record keeping**
- **Authorisation of Operators**
 - Licensing
 - Registration



.../...

- **Monitoring of exports**
 - Pre-export notifications (MCRN)
 - Individual export authorisations
 - Simplified export authorisation procedures
- **General focus on the "Key substances"**
- **Monitoring of imports**
 - Individual import authorisations for the most sensitive drug precursors
 - General monitoring of transshipment movements



.../...

- **Co-operation with Industry**

- Basic pattern remains diversion from licit trade
- First line of defense in seeing suspicious orders
- To inform about suspicious transactions
- « Reporting » obligations
- To foster « preventive approach »
- Voluntary co-operation/flexibility

.../...



.../...

- **EC Voluntary Monitoring List**
- **Industry Guidelines**
 - Effective tool of « co-operation »
 - Required through the legislation
 - To facilitate the application of the legal provisions
 - To make industry aware of its obligations



4. Challenges

- New patterns of diversion
- Tremendous turnover of goods
- Place of illicit synthetic drug manufacture
 - need to source required precursors outside EC
- EC still produces and/or exports drug precursors



5. The operational side

- Project “**COHESION**”, Project “**PRISM**”
- Need to enhance precursor specific border controls in all transport vectors (import + transshipment + export)
- Need to develop + to apply criteria to target consignments
- Backtracking: Identifying the sources to effectively cut down supply



6. Future Developments

- Natural Products (safrole rich oils – ephedra etc.)
- Methamphetamine/diversion of pharmaceutical preparations in the Community ?
- Strengthened co-operation with China
- Increased customs controls



Thank you for listening !

For further questions:

- 1) **Suzanne Stauffer**, DG TAXUD, Tel. +32.2.295.6978
email: Suzanne.Stauffer@cec.eu.int (External trade in Drug precursors)
- 2) **Laurence Cordier**, DG Entreprise, Tel. +32.2.2964843
email: Laurence.Corder@cec.eu.int (Intra-Community trade in drug precursors)